Fennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record High
Fennec's Pedmark is reportedly in demand as the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
Fennec's Pedmark is reportedly in demand as the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
Ampetronic and Listen Technologies' Auri system, an Auracast broadcast audio-based assistive listening solution, has been permanently installed at Brighton station in the UK — marking a milestone for audio accessibility in the country's rail network.
The ADA's new initiative offers dollar-for-dollar dues matching and complimentary memberships to encourage dual participation at the state and national level.
A federal court has issued a preliminary injunction halting the Department of Education’s narrowed definition of “professional degree,” temporarily restoring higher federal borrowing limits for Doctor of Audiology students.
Read MoreOticon is accepting nominations for its annual awards program recognizing individuals with hearing loss and the professionals, caregivers, and educators who champion hearing health.
Read MoreMed-El has acquired two gene therapy programs from Rescue Hearing Inc targeting mutations in the MYO7A and STRC genes, expanding the hearing implant company’s pipeline into biological approaches to vestibular and auditory dysfunction.
Read MoreThe biotech secures improved royalty terms on its two lead hearing loss programs, CIL001 and CIL003, while Sanofi takes a minority stake in the company.
Read MoreThe FCC-certified captioning app’s AI-powered TTS features earned the company the “Text to Speech Solution of the Year” recognition in the ninth annual AI Breakthrough Awards program.
Read MoreMore than 100 Oticon employees joined Community Hope’s 2026 Flag Day 5K and Fun Walk, marking the largest team turnout in the event’s history for the hearing healthcare company.
Read MoreThe Eden Prairie-based hearing technology company’s latest recognition is based entirely on employee feedback and follows a string of workplace and culture awards in recent years.
Read MoreThe national hearing care company, part of the Demant Group, continues expanding its community-level footprint with a new location in Northern Virginia.
Read MoreThe ProHear Study found that the drug candidate Bimokalner produced a clinically meaningful reduction in pure-tone audiometry threshold shifts in testicular cancer patients who developed cisplatin-induced ototoxicity.
Read MoreAs chair, Amlani will lead efforts to expand the department’s educational, research, and clinical impact.
Read MoreSensorion is focusing on SENS-601 targeting GJB2 mutations, while discontinuing development of its OTOF-targeting program, SENS-501.
Read MoreThe veteran disability rights attorney and telecommunications advocate will join the board effective July 1, 2026, bringing decades of federal policy experience.
Read MoreBIHIMA is inviting hearing care professionals across the UK and Ireland to participate in its 2026 audiologist survey, with findings slated for publication later this year.
Read MoreBIHIMA data for Q1 2026 shows increases in ROI sales and UK private sales compared to Q4 2025, with a notable rise in NHS adoption of rechargeable devices.
Read MoreThe partnership will integrate NationsHearing clinical services and technology into the retail club’s locations across the US.
Read More